Candel Therapeutics (CADL) Depreciation & Amortization (CF) (2020 - 2025)
Candel Therapeutics (CADL) reported Depreciation & Amortization (CF) of $118000.0 for Q4 2025, down 59.31% on a YoY basis from $290000.0 in Q4 2024, and down 41.0% sequentially from $200000.0 in Q3 2025.
Candel Therapeutics (CADL) Depreciation & Amortization (CF) (2020 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $118000.0 in Q4 2025.
- For the quarter ending Q4 2025, Depreciation & Amortization (CF) fell 59.31% year-over-year to $118000.0; the trailing twelve-month figure through Dec 2025 stood at $718000.0 (down 27.47% YoY), and the FY2025 full-year result was $800000.0, down 19.19% from the prior year.
- Depreciation & Amortization (CF) eased to $118000.0 in Q4 2025, from $200000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $300000.0 in Q1 2024 to a low of $7000.0 in Q2 2021.
- A 5-year average of $179250.0 and a median of $200000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) soared 2866.67% in 2021 and sank 59.31% in 2025, its largest moves.
- Tracing CADL's Depreciation & Amortization (CF) over 5 years: stood at $178000.0 in 2021, then changed by 0.0% to $178000.0 in 2022, then soared by 39.89% to $249000.0 in 2023, then advanced by 16.47% to $290000.0 in 2024, then slumped by 59.31% to $118000.0 in 2025.
- Business Quant data shows CADL's Depreciation & Amortization (CF) at $118000.0 in Q4 2025, $200000.0 in Q3 2025, and $200000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | 118,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 118,000.00 |
| Dec 31, 2025 | 118,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 290,000.00 |
| Dec 31, 2024 | 290,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Mar 31, 2024 | 300,000.00 |
| Dec 31, 2023 | 249,000.00 |
| Dec 31, 2023 | 249,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Sep 30, 2023 | 200,000.00 |